Published in Rheumatology (Oxford) on March 23, 2004
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther (2009) 1.14
Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis (2007) 1.11
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes (2014) 0.88
Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis (2014) 0.82
Toward characterization and definition of fibromyalgia severity. BMC Musculoskelet Disord (2010) 0.81
Relative responsiveness of physician/assessor-derived and patient-derived core set measures in rheumatoid arthritis trials. J Rheumatol (2008) 0.81
Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis (2008) 0.79
Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther (2009) 0.79
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther (2016) 0.78
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis (2016) 0.77
Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring. Arthritis Res Ther (2013) 0.77
ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology (Oxford) (2015) 0.77
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open (2017) 0.75
A global measure of perceived stress. J Health Soc Behav (1983) 56.90
THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest (1945) 27.11
Stress, social support, and the buffering hypothesis. Psychol Bull (1985) 19.28
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Socioeconomic status and health. The challenge of the gradient. Am Psychol (1994) 13.59
Epidermal growth factor. Annu Rev Biochem (1979) 11.82
125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol (1976) 10.88
Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J Biol Chem (1972) 10.86
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science (2001) 8.12
Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem (1980) 7.71
Beta Alanine as a Growth Accessory for the Diphtheria Bacillus. J Bacteriol (1937) 7.51
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci U S A (1978) 5.91
Direct visualization of the binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431. J Cell Biol (1979) 5.62
Does hiatus hernia affect competence of the gastroesophageal sphincter? N Engl J Med (1971) 5.44
Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem (1980) 5.19
Epidermal growth factor. J Biol Chem (1990) 4.79
Prophylactic vs therapeutic blood patch for obstetric patients with accidental dural puncture--a randomised controlled trial. Anaesthesia (2014) 4.75
IMMUNITY IN MUMPS : II. THE DEVELOPMENT OF COMPLEMENT-FIXING ANTIBODY AND DERMAL HYPERSENSITIVITY IN HUMAN BEINGS FOLLOWING MUMPS. J Exp Med (1945) 4.69
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
The primary structure of epidermal growth factor. J Biol Chem (1972) 4.41
Epidermal growth factor: morphological demonstration of binding, internalization, and lysosomal association in human fibroblasts. Proc Natl Acad Sci U S A (1978) 4.03
Human epidermal growth factor and the proliferation of human fibroblasts. J Cell Physiol (1976) 3.91
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem (1982) 3.81
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
IN VITRO AND IN VIVO EFFECTS OF A NERVE GROWTH-STIMULATING AGENT ISOLATED FROM SNAKE VENOM. Proc Natl Acad Sci U S A (1956) 3.64
THE INFLUENCE OF PROTEIN INTAKE ON THE UREA CLEARANCE IN NORMAL MAN. J Clin Invest (1934) 3.60
Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature (1976) 3.56
Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature (1978) 3.54
Hormone receptor topology and dynamics: morphological analysis using ferritin-labeled epidermal growth factor. Proc Natl Acad Sci U S A (1979) 3.54
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature (2000) 3.51
Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J Biol Chem (1975) 3.48
Induction by EGF and interferon-gamma of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. Science (1993) 3.30
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Heterogeneity of the peptide chains of gamma-globulin. Biochem J (1964) 3.25
Action of malarial antibody in vitro. Nature (1969) 3.24
Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor. J Biol Chem (1979) 3.18
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med (1999) 3.10
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun (1982) 3.01
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
ABC of intensive care. Withdrawal of treatment. BMJ (1999) 2.96
Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci U S A (1975) 2.95
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
Social support and smoking cessation and maintenance. J Consult Clin Psychol (1986) 2.92
Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J Cell Biol (1979) 2.88
The production of migration inhibition factor by B and T cells of the guinea pig. J Exp Med (1973) 2.86
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet (1999) 2.83
Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet (1987) 2.81
Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol (1988) 2.79
In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics. Antimicrob Agents Chemother (1976) 2.75
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol (1989) 2.72
Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis (1984) 2.67
Properties of protective malarial antibody. Immunology (1970) 2.65
Rapid induction of morphological changes in human carcinoma cells A-431 by epidermal growth factors. J Cell Biol (1979) 2.61
Evidence for high-energy extraterrestrial neutrinos at the IceCube detector. Science (2013) 2.56
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol (1984) 2.54
A simple technique to reduce the incidence of accidental dural puncture. Anaesthesia (2001) 2.53
Stress and immunity in humans: a meta-analytic review. Psychosom Med (1993) 2.52
Conjugational transfer of gentamicin resistance plasmids intra- and interspecifically in Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1983) 2.50
The distribution of antigenic and nonantigenic compounds within draining lymph nodes. Lab Invest (1966) 2.49
Identity and interspecific transfer of gentamicin-resistance plasmids in Staphylococcus aureus and Staphylococcus epidermidis. J Infect Dis (1980) 2.48
Enhancement of calcium uptake and phosphatidylinositol turnover by epidermal growth factor in A-431 cells. Biochemistry (1981) 2.46
Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Health Psychol (1996) 2.46
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Inconsistent visual analyses of intrasubject data. J Appl Behav Anal (1979) 2.43
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
A merozoite vaccine effective against Plasmodium knowlesi malaria. Nature (1974) 2.39
Sensorimotor changes and functional performance in patients with knee osteoarthritis. Ann Rheum Dis (1997) 2.39
Group support interventions for women with breast cancer: who benefits from what? Health Psychol (2000) 2.38
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
Review of psychosocial stress and asthma: an integrated biopsychosocial approach. Thorax (1998) 2.33
Depression and immunity: a meta-analytic review. Psychol Bull (1993) 2.30
Investigation of benefits and costs of an ophthalmic outreach clinic in general practice. Br J Gen Pract (1995) 2.26
Absence of circular plasmid deoxyribonucleic acid attributable to a genetic determinant for methicillin resistance in Staphylococcus aureus. J Bacteriol (1973) 2.25
Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium? Circulation (2000) 2.25
Our new President: Frank P. Brooks. Gastroenterology (1980) 2.24
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Cytoplasmic pH regulation in thymic lymphocytes by an amiloride-sensitive Na+/H+ antiport. J Gen Physiol (1984) 2.23
In vitro isolation of Plasmodium knowlesi merozoites using polycarbonate sieves. Parasitology (1975) 2.23
Cimetidine in the treatment of symptomatic gastroesophageal reflux: a double blind controlled trial. Gastroenterology (1978) 2.21
Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells. J Biol Chem (1984) 2.21
Merozoite vaccination against Plasmodium knowlesi malaria. Immunology (1975) 2.21
Mesiotemporal T2-weighted hyperintensity: neurosyphilis mimicking herpes encephalitis. AJNR Am J Neuroradiol (2001) 2.16
The way forward for hydrotherapy. Br J Rheumatol (1993) 2.15
Cause of death in rheumatoid arthritis. Br J Rheumatol (1984) 2.12
The clinical features of chronic vitamin deficiency. A therapeutic trial in geriatric hospital patients. Gerontol Clin (Basel) (1968) 2.09
Structure and biological properties of immunoglobulins. Adv Immunol (1967) 2.08
Hormonal regulation of human lower esophageal sphincter competence: interaction of gastrin and secretin. J Clin Invest (1971) 2.07
Colonic myoelectric activity in the irritable bowel syndrome. Gastroenterology (1976) 2.05